Aridis is a late-stage biopharmaceutical company focused on discovering and developing innovative anti-infectives, such as targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening infections.
“AR-501 has the potential to offer patients more convenient dosing (once per week) versus standard- of-care inhaled antibiotics (several times per day),” and with a “more effective delivery route than (IV) administered gallium,” CEO Vu Truong said.
https://investors.aridispharma.com/...is-Awarded-FDA-Expedited-Program-Designations
“AR-501 has the potential to offer patients more convenient dosing (once per week) versus standard- of-care inhaled antibiotics (several times per day),” and with a “more effective delivery route than (IV) administered gallium,” CEO Vu Truong said.
https://investors.aridispharma.com/...is-Awarded-FDA-Expedited-Program-Designations